Checkpoint Therapeutics Stock News

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J

WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that J

Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that Jam

Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that m

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) shares, rose in value on Thursday, 03/10/22, with the stock price up by 13.77% to the previous day’s close as strong demand from buyers drove the stock to $1.90. Actively observing the price movement in the last trading, the stock closed the session at $1.67, falling within a range of $1.61 … Analysts Predict A Surge In Checkpoint Therapeutics Inc. (NASDAQ: CKPT)? Read More »

Checkpoint Therapeutics Inc. (NASDAQ:CKPT) concluded the trading at $1.85 on Thursday, February 24 with a rise of 4.52% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.77 and 5Y monthly beta was reading 1.65 with its price kept floating in the … Analysts Predict How High Checkpoint Therapeutics Inc. (CKPT) Will Go. Read More »

In last trading session, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) saw 0.87 million shares changing hands with its beta currently measuring 1.69. Companys recent per share price level of $2.39 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $185.56M. That closing price of CKPTs stock is Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Stock Plunged -23.15% So Far In 2022, What Analysts Expect Next? Read More »

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Checkpoint Therapeutics Inc (NASDAQ: CKPT ) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4%. The median duration of response (DOR) had Full story available on Benzinga.com

Checkpoint Therapeutics (CKPT) announces positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody,

The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 13% during intraday trading. This is why it happened.

Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.